Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial
Numerical differences in retinal thickness fluctuations between months 3 and 6 were detected between treatment regimens. While the presence of fluctuations has previously been shown to have a negative impact on functional outcomes, our data showed no correlation between the mean amplitude of fluctuations and functional outcomes at month 12.
Authors
- Lebriz Altay (ORCID: https://orcid.org/0000-0003-1088-3786)
- Sandra Liakopoulos (ORCID: https://orcid.org/0000-0003-3539-4372)
- Claudia Quiering
- Frank Gerhard Holz (ORCID: https://orcid.org/0000-0001-8019-9272)
- Rufino Silva (ORCID: https://orcid.org/0000-0001-8676-0833)
- Michael Larsen (ORCID: https://orcid.org/0000-0002-5172-5891)
- Uwe Rose (ORCID: https://orcid.org/0000-0002-0170-6297)
- Eric H. Souied (ORCID: https://orcid.org/0000-0001-9388-202X)
- Hansjuergen Agostini
Institutions
- Goethe University Frankfurt (DE)
- University of Copenhagen (DK)
- University of Bonn (DE)
- University of Freiburg (DE)
- University of Cologne (DE)
- Rigshospitalet (DK)
- Novartis (Germany) (DE)
- LVR-Klinik Köln (DE)
- Centrum für Integrierte Onkologie (DE)
- Hôpital Intercommunal de Créteil (FR)
- University of Coimbra (PT)
Publication Details
- Journal
- British Journal of Ophthalmology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1136/bjo-2024-326526
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharma